OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

A phase 2 trial of Farletuzumab-exatecan, Bevacizumab, Carboplatin in ovarian cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.